Across TCGA pan-cancer cohorts, PCGF3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PCGF3 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PCGF3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCGF3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LUAD are the cancer types where PCGF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.677	.001	44	view →
GBM	DFS	Tertile	All	0.649	0.230	.024	6	view →
LUAD	DFS	Tertile	III,IV	0.915	0.511	.024	3	view →
LSCC	DFS	Quartile	All	1.000	0.854	.014	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PCGF3 tumor-vs-normal RNA expression · all PCGF3 data types